This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Novo Nordisk Promotes Four Members Of U.S. Leadership Team To Senior Vice President

Stocks in this article: NVO

PRINCETON, N.J., Jan. 31, 2013 /PRNewswire/ -- Novo Nordisk (NYSE: NVO), a global healthcare company with 90 years of innovation and leadership in diabetes care, announced the promotion of four corporate vice presidents to senior vice presidents. Effective March 1, 2013, the following members of the U.S. Executive Team will assume the title of senior vice president in their respective areas:  Andy Ajello, U.S. National Diabetes Sales; Camille Lee, U.S. Diabetes Marketing; Alan Moses, MD, global chief medical officer; and Anne Phillips, MD, U.S. Clinical, Medical and Regulatory Affairs. 

"The size and complexity of the U.S. business has increased dramatically, which places great demands on our leaders," said Jerzy Gruhn, president of Novo Nordisk Inc., the company's US affiliate.  "Our global leaders have recognized that certain positions within the U.S. organization now have such high impact on the company's overall performance that they should be elevated to the senior vice president level. The same is true for the role of Global Chief Medical Officer, which has grown in impact with the increasing number of promising projects in our development pipeline."

Andy, Camille and Anne will continue to serve on the U.S. Executive Team, reporting to Jerzy.  Alan will move to the company's global headquarters in Denmark and report to Mads Krogsgaard Thomsen, executive vice president and chief science officer, later in 2013.  All will become members of the company's senior management board, a group comprised of Novo Nordisk's senior-most leaders.

Andy has been in the pharmaceutical industry for nearly 20 years. He joined Novo Nordisk in March 2001 and currently leads the National Diabetes Sales strategy and the company's approximately 3,200 person field sales organization. During his 12 years with the company, he has been widely recognized for developing and motivating a high-performing sales team. His responsibilities include oversight of the entire diabetes sales organization, including managed markets sales, field force operations, and strategic sales initiatives.

Camille has more than 25 years of experience in the industry. She joined Novo Nordisk in 1985 as a sales representative in Southern California, and through her tenure with the company has held national and international positions of increasing authority in the areas of marketing, strategic launch planning, and sales management. Over the past six years, she has built a strong diabetes marketing team of 365 people that has been recognized internally and externally for their best-in-class initiatives.  She currently has oversight for the marketing of all in-line and future brands, as well as the organization's Diabetes Educator Program.

Alan joined Novo Nordisk in 2004 from Harvard Medical School and the Joslin Diabetes Center as associate vice president for clinical research and medical affairs – endocrinology, and in 2007 was named chief medical officer for North America. One year later, he was appointed to global chief medical officer. He is involved in the full spectrum of Novo Nordisk's diverse diabetes work from drug discovery to addressing the implications of diabetes for patients, healthcare professionals, and healthcare systems.

Anne brings more than 20 years of medical, research, and regulatory experience to her role. She currently leads an integrated drug development, medical, regulatory, and safety team of more than 550 people, and plays a key role in advancing Novo Nordisk's diabetes and biopharmaceutical clinical development pipelines. She is responsible for the efficient development and delivery of compounds in clinical trials, including product lifestyle and in-licensed compounds.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs